<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Emory_Design skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Emory/Design</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Team:Emory iGEM 2016</TITLE></P><UL><LI class="active"><A href="https://2016.igem.org/Team:Emory">HOME</A></LI><LI><A href="#">PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Design">Design</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Experiments">Experiments</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Proof">Proof of Concept</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Results">Results</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Notebook">Notebook</A></LI></UL><LI><A href="#">PARTS</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Safety">SAFETY</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Human_Practices">COMMUNITY INVOLVEMENT</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Collaborations">COLLABORATIONS</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Team">TEAM</A></LI><LI><A href="https://2016.igem.org/Team:Emory/Attributions">ATTRIBUTIONS</A></LI></DIV></DIV><DIV id="project"><DIV class="container"><H1 style="text-align:center;font-size:50px;color:#343738;font-family:Open Sans, Arial, Helvetice Neue, sans-serif;padding-top:150px;">DESIGN</H1><P style="text-align:right;padding-bottom:70px;">Synthetic Biology is largely restricted to well-funded laboratories at major research universities in high income countries. One significant barrier to entry is the capital cost of instruments. The cloning and assembly of BioBricks, for example, includes the transformation of Escherichia coli, which requires the purchase of a refrigerated centrifuge and an ultra-cold freezer. Here we assemble BioBrick-compatible shuttlevectors for Acinetobacter baylyi ADP1, a naturally competent relative of E. coli that grows as rapidly under identical conditions. We will show that A. baylyi can be transformed with recombinant DNA simply by adding ligation reactions to mid-log cultures; transformants are selected as usual by spreading them onto LB agar plates supplemented with the appropriate antibiotics (kanamycin, spectinomycin, tetracycline, cefotaxime or amikacin). These experiments will show how BioBricks can be constructed and assembled in modestly funded laboratories in community colleges.</P></DIV></DIV></DIV></DIV></DIV></BODY></HTML>